Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
High Hypothetical Interest in Physician-Assisted Death in Multiple Sclerosis
Neurol 88:1528-1534, Marrie, R.A.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Five Cases of Malignant Melanoma During Fingolimod Treatment in Dutch Patients with MS
Neurol 89:970-972, Killestein, J.,et al, 2017
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
The Useless Hand of Oppenheim
Pract Neurol 17:464-468, Wiblin, L. & Guadagno, J., 2017
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Acute Disseminated Encephalomyelitis in 228 Patients
Neurol 86:2085-2096, Koelman, D.L.H.,et al, 2016
Malignancies after Mitoxantrone for Multiple Sclerosis
Neurol 86:2203-2207, Buttmann, M.,et al, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Rebound Syndrome in Patients with Multiple Sclerosis after Cessation of Fingolimod Treatment
JAMA Neurol 73:790-794, Hatcher, S.E.,et al, 2016
Incidence of Radiologically Isolated Syndrome: A Population-Based Study
AJNR 37:1017-1022, Forslin, Y.,et al, 2016
Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016
Acute Idiopathic Transverse Myelitis in Children
Neurol 84:341-349,332, Deiva, K.,et al, 2015
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Investigation of Leptomeningeal Enhancement in MS
Neurol 84:770-775, Eisele, P.,et al, 2015
Relapse in Multiple Sclerosis
BMJ 350:h1765, Galea, I.,et al, 2015
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Paroxysmal Dystonia as a Manifestation of Multiple Sclerosis
Neurologist 19:132-134, Machado, C.,et al, 2015
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP):A Randomised, Controlled, Double-Blind,Non-Inferiority Trial
Lancet 386:974-981, LePage,E.,et al, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Isolated Lingual Dyskinesia in Multiple Sclerosis
JAMA Neurol 72:1196-1197, Park, J.E.,et al, 2015
Cryptococcal Meningoencephalitis in a Patient with Multiple Sclerosis Treated with Fingolimod
JAMA Neurol 72:1203-1205, Zhan, Y.,et al, 2015
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
JAMA Neurol 71:954-960, Clerico, M.,et al, 2014
CD49d Antisense Drug ATL1102 Reduces Disease Activity in Patients with Relapsing-Remitting MS
Neurol 83:1780-1788, Limmroth, V.,et al, 2014
Effects of Bacille Calmette-Guerin after the first Demyelinating event in the CNS
Neurol 82:41-48, Ristori, G.,et al, 2014
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014
Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014
Relapsing-Remitting Tumefactive Demyelination
JAMA Neurol 71:366-367, Brandao, E.,et al, 2014
Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:e103-e104, Fox, R.J., 2014
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Intensive Care Unit Admission in Multiple Sclerosis
Neurol 82:2112-2119, Marrie, R.A.,et al, 2014
Balos Concentric Sclerosis
Lancet Neurol 13:740-746, Hardy, T.A. & Miller, D.H., 2014
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014